164391-47-3 Usage
Description
4-(1H-IMIDAZOL-4-YLMETHYL)PIPERIDINE DIHYDROBROMIDE, also known as Immepip, is a selective nonchiral histamine H3 receptor agonist with high affinity for the human histamine H3 receptor (KI = 0.4 nM). It is a crystalline solid that selectively targets histamine H3 over H1 and H2 receptors, while also agonizing H4 receptors (KI = 9 nM). Immepip has demonstrated effects on hypothalamic histamine release and has shown potential in reducing pain and inflammation in animal models.
Uses
Used in Pharmaceutical Industry:
4-(1H-IMIDAZOL-4-YLMETHYL)PIPERIDINE DIHYDROBROMIDE is used as a selective nonchiral histamine H3 agonist for its potential therapeutic applications in various conditions. It is particularly useful in the development of drugs targeting histamine H3 receptors, which play a role in cognitive functions, wakefulness, and energy homeostasis.
Used in Research Applications:
In the field of scientific research, 4-(1H-IMIDAZOL-4-YLMETHYL)PIPERIDINE DIHYDROBROMIDE is used as a research tool to study the role of histamine H3 receptors in various physiological processes and to investigate the potential therapeutic effects of histamine H3 agonists on conditions such as pain, inflammation, and cognitive disorders.
Used in Drug Development:
4-(1H-IMIDAZOL-4-YLMETHYL)PIPERIDINE DIHYDROBROMIDE is used as a lead compound in the development of new drugs targeting histamine H3 receptors. Its high selectivity and affinity for the receptor make it a valuable starting point for designing more potent and selective histamine H3 agonists with improved pharmacological properties.
Used in Neuropharmacology:
In the field of neuropharmacology, 4-(1H-IMIDAZOL-4-YLMETHYL)PIPERIDINE DIHYDROBROMIDE is used as a selective histamine H3 agonist to study the role of histamine H3 receptors in the central nervous system. This includes investigating their involvement in wakefulness, sleep-wake cycles, and cognitive functions, as well as their potential as targets for the treatment of neurological disorders.
Biological Activity
Potent histamine H 3 receptor agonist. Also binds to H 4 receptors (K i values are 0.4 and 9 nM at human recombinant H 3 and H 4 receptors respectively). Equipotent to or slightly more active than (R)- α -methylhistamine at H 3 receptors.
Check Digit Verification of cas no
The CAS Registry Mumber 164391-47-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,4,3,9 and 1 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 164391-47:
(8*1)+(7*6)+(6*4)+(5*3)+(4*9)+(3*1)+(2*4)+(1*7)=143
143 % 10 = 3
So 164391-47-3 is a valid CAS Registry Number.
InChI:InChI=1/C9H15N3.2BrH/c1-3-10-4-2-8(1)5-9-6-11-7-12-9;;/h6-8,10H,1-5H2,(H,11,12);2*1H
164391-47-3Relevant articles and documents
N-substituted piperidinyl alkyl imidazoles: Discovery of methimepip as a potent and selective histamine H3 receptor agonist
Kitbunnadaj, Ruengwit,Hashimoto, Takeshi,Poli, Enzo,Zuiderveld, Obbe P.,Menozzi, Alessandro,Hidaka, Ryoko,De Esch, Iwan J. P.,Bakker, Remko A.,Menge, Wiro M. P. B.,Yamatodani, Atsushi,Coruzzi, Gabriella,Timmerman, Henk,Leurs, Rob
, p. 2100 - 2107 (2007/10/03)
In this study, we continue our efforts toward the development of potent and highly selective histamine H3 receptor agonists. We introduced various alkyl or aryl alkyl groups on the piperidine nitrogen of the known H3/H4 agonist immepip and its analogues (1-3a). We observed that N-methyl-substituted immepip (methimepip) exhibits high affinity and agonist activity at the human histamine H3 receptor (pK i = 9.0 and pEC50 = 9.5) with a 2000-fold selectivity at the human H3 receptor over the human H4 receptor and more than a 10000-fold selectivity over the human histamine H1 and H 2 receptors. Methimepip was also very effective as an H3 receptor agonist at the guinea pig ileum (pD2 = 8.26). Moreover, in vivo microdialysis (in rat brain) showed that methimepip reduces the basal level of brain histamine to about 25% after a 5 mg/kg intraperitoneal administration.
